82 related articles for article (PubMed ID: 15683813)
1. Keeping pace with innovation.
Lancet Oncol; 2005 Feb; 6(2):65. PubMed ID: 15683813
[No Abstract] [Full Text] [Related]
2. Gefitinib does not increase survival in lung cancer patients.
Golsteyn RM
Drug Discov Today; 2005 Mar; 10(6):381. PubMed ID: 15808815
[No Abstract] [Full Text] [Related]
3. FDA Oncology Committee debates Iressa's status following negative trial results.
Twombly R
J Natl Cancer Inst; 2005 Apr; 97(7):473. PubMed ID: 15812066
[No Abstract] [Full Text] [Related]
4. Cancer drugs. Smart weapons prove tough to design.
Couzin J
Science; 2002 Oct; 298(5593):522-5. PubMed ID: 12386312
[No Abstract] [Full Text] [Related]
5. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.
Friedrich MJ
J Natl Cancer Inst; 2009 Aug; 101(15):1039-41. PubMed ID: 19638503
[No Abstract] [Full Text] [Related]
6. FDA announces fast track approval of new drug for lung cancer.
Dyer O
BMJ; 2003 May; 326(7397):1004. PubMed ID: 12742913
[No Abstract] [Full Text] [Related]
7. Failing survival advantage in crucial trial, future of Iressa is in jeopardy.
Twombly R
J Natl Cancer Inst; 2005 Feb; 97(4):249-50. PubMed ID: 15713955
[No Abstract] [Full Text] [Related]
8. Despite concerns, FDA panel backs EGFR inhibitor.
Twombly R
J Natl Cancer Inst; 2002 Nov; 94(21):1596-7. PubMed ID: 12419780
[No Abstract] [Full Text] [Related]
9. Iressa's fall from grace points to need for better clinical trials.
Singer E
Nat Med; 2005 Feb; 11(2):107. PubMed ID: 15692580
[No Abstract] [Full Text] [Related]
10. Conflicting signals on US accelerated approvals.
Fox JL
Nat Biotechnol; 2005 Sep; 23(9):1027-8. PubMed ID: 16151377
[No Abstract] [Full Text] [Related]
11. Clinical trial of Iressa.
FDA Consum; 2005; 39(2):4. PubMed ID: 16121415
[No Abstract] [Full Text] [Related]
12. A deadly disease, a promising drug.
Fischman J
US News World Rep; 2004 May; 136(16):65. PubMed ID: 15164564
[No Abstract] [Full Text] [Related]
13. Gefitinib: phoenix from the flames.
Lancet Oncol; 2009 Aug; 10(8):737. PubMed ID: 19647191
[No Abstract] [Full Text] [Related]
14. Gefitinib.
Muhsin M; Graham J; Kirkpatrick P
Nat Rev Drug Discov; 2003 Jul; 2(7):515-6. PubMed ID: 12841190
[No Abstract] [Full Text] [Related]
15. [Erlotinib. A new option for non-small cell lung cancer].
Polk B
Med Monatsschr Pharm; 2006 Jan; 29(1):4-6. PubMed ID: 16463547
[No Abstract] [Full Text] [Related]
16. Selecting the right patient for tumor therapy.
Arteaga CL
Nat Med; 2004 Jun; 10(6):577-8. PubMed ID: 15170197
[No Abstract] [Full Text] [Related]
17. Iressa : first angiogenesis inhibitor approved for the treatment of advanced NSCLC.
Expert Rev Anticancer Ther; 2003 Jun; 3(3):257. PubMed ID: 12820770
[No Abstract] [Full Text] [Related]
18. Cancer medicine hits a target.
Sobel RK
US News World Rep; 2002 Jun; 132(19):54. PubMed ID: 12066454
[No Abstract] [Full Text] [Related]
19. Gefitinib in patients with non-small cell lung cancer: symptomatic improvement within a few days.
Bearz A; Vaccher E; Spazzapan S; Berretta M; Tirelli U
Lung Cancer; 2005 Sep; 49(3):417-8. PubMed ID: 16102608
[No Abstract] [Full Text] [Related]
20. Accelerated approval scrutinized: confirmatory phase 4 studies on new drugs languish.
Mitka M
JAMA; 2003 Jun; 289(24):3227-9. PubMed ID: 12824196
[No Abstract] [Full Text] [Related]
[Next] [New Search]
